Clinical Trial

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 29, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06663059
Lead Sponsor Tang-Du Hospital
Conditions Esophageal Cancer
Enrollment 80 participants
Start Date 2024-10-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-29